Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors
This study is currently recruiting participants.
Study NCT00555724   Information provided by Biogen Idec
First Received: October 31, 2007   Last Updated: July 10, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Solid Tumors
Additional conditions recognized in this trial
Neoplasms
Interventions listed in this trial
BIIB022
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Biogen Idec


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services